Status:

COMPLETED

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Lead Sponsor:

Arcus Biosciences, Inc.

Collaborating Sponsors:

Gilead Sciences

Conditions:

Advanced Solid Tumor

Non Small Cell Lung Cancer (NSCLC)

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB30...

Eligibility Criteria

Inclusion

  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Male or female participants ≥ 18 years of age (or age ≥ regionally approved age of consent for participation in investigational clinical studies) at the time of signing the informed consent.
  • Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Adequate organ and marrow function

Exclusion

  • History of trauma or major surgery within 28 days prior to the first dose of study treatment.
  • Prior treatment with an anti-TIGIT antibody.
  • Any active or prior autoimmune disease that required treatment within 3 years of the first dose of study treatment.
  • Prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic agents, or use of other investigational drugs within 28 days before first dose of study treatment.
  • Discontinued prior immunotherapy for immune related adverse events with a high severity.
  • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Key Trial Info

Start Date :

March 19 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 25 2025

Estimated Enrollment :

94 Patients enrolled

Trial Details

Trial ID

NCT04772989

Start Date

March 19 2021

End Date

August 25 2025

Last Update

August 28 2025

Active Locations (22)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (22 locations)

1

UCLA Department of Medicine - Hematology/Oncology

Los Angeles, California, United States, 90095

2

Mayo Clinic Jacksonville - PPDS

Jacksonville, Florida, United States, 32224

3

Goshen Health System

Goshen, Indiana, United States, 46526

4

Holden Comprehensive Cancer Center

Iowa City, Iowa, United States, 52242

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | DecenTrialz